Nova Zelanda - anglès - Medsafe (Medicines Safety Authority)

arrotex pharmaceuticals (nz) limited - atomoxetine hydrochloride 20.574mg equivalent to atomoxetine 18mg - capsule - 18 mg - active: atomoxetine hydrochloride 20.574mg equivalent to atomoxetine 18mg excipient: colloidal silicon dioxide croscarmellose sodium gelatin   iron oxide yellow magnesium stearate opacode black s-1-277002 starch titanium dioxide   - treatment of attention deficit hyperactivity disorder (adhd) as defined by dsm-iv criteria in children 6 years of age and older, adolescents and adults.

Nova Zelanda - anglès - Medsafe (Medicines Safety Authority)

arrotex pharmaceuticals (nz) limited - atomoxetine hydrochloride 28.575mg equivalent to atomoxetine 25mg - capsule - 25 mg - active: atomoxetine hydrochloride 28.575mg equivalent to atomoxetine 25mg excipient: colloidal silicon dioxide croscarmellose sodium gelatin   indigo carmine magnesium stearate opacode black s-1-277002 starch titanium dioxide   - treatment of attention deficit hyperactivity disorder (adhd) as defined by dsm-iv criteria in children 6 years of age and older, adolescents and adults.

Nova Zelanda - anglès - Medsafe (Medicines Safety Authority)

arrotex pharmaceuticals (nz) limited - atomoxetine hydrochloride 45.72mg equivalent to atomoxetine 40mg - capsule - 40 mg - active: atomoxetine hydrochloride 45.72mg equivalent to atomoxetine 40mg excipient: colloidal silicon dioxide croscarmellose sodium gelatin   indigo carmine   magnesium stearate opacode black s-1-277002 starch titanium dioxide   - treatment of attention deficit hyperactivity disorder (adhd) as defined by dsm-iv criteria in children 6 years of age and older, adolescents and adults.

Nova Zelanda - anglès - Medsafe (Medicines Safety Authority)

arrotex pharmaceuticals (nz) limited - atomoxetine hydrochloride 5.715mg equivalent to atomoxetine 5mg - capsule - 5 mg - active: atomoxetine hydrochloride 5.715mg equivalent to atomoxetine 5mg excipient: colloidal silicon dioxide croscarmellose sodium gelatin   iron oxide yellow   magnesium stearate opacode black s-1-277002 starch titanium dioxide   - treatment of attention deficit hyperactivity disorder (adhd) as defined by dsm-iv criteria in children 6 years of age and older, adolescents and adults.

Nova Zelanda - anglès - Medsafe (Medicines Safety Authority)

arrotex pharmaceuticals (nz) limited - atomoxetine hydrochloride 68.58mg equivalent to atomoxetine 60mg - capsule - 60 mg - active: atomoxetine hydrochloride 68.58mg equivalent to atomoxetine 60mg excipient: colloidal silicon dioxide croscarmellose sodium gelatin   indigo carmine iron oxide yellow magnesium stearate opacode black s-1-277002 starch titanium dioxide   - treatment of attention deficit hyperactivity disorder (adhd) as defined by dsm-iv criteria in children 6 years of age and older, adolescents and adults.

Nova Zelanda - anglès - Medsafe (Medicines Safety Authority)

arrotex pharmaceuticals (nz) limited - atomoxetine hydrochloride 91.44mg equivalent to atomoxetine 80mg - capsule - 80 mg - active: atomoxetine hydrochloride 91.44mg equivalent to atomoxetine 80mg excipient: colloidal silicon dioxide croscarmellose sodium gelatin   iron oxide black iron oxide red iron oxide yellow magnesium stearate opacode black s-1-277002 starch titanium dioxide   - treatment of attention deficit hyperactivity disorder (adhd) as defined by dsm-iv criteria in children 6 years of age and older, adolescents and adults.

Nova Zelanda - anglès - Medsafe (Medicines Safety Authority)

arrotex pharmaceuticals (nz) limited - melatonin 2mg;   - modified release tablet - 2 mg - active: melatonin 2mg   excipient: calcium hydrogen phosphate dihydrate colloidal silicon dioxide lactose monohydrate magnesium stearate methacrylic acid copolymer purified talc - indicated as a monotherapy for the short-term treatment of primary insomnia characterised by poor quality of sleep in patients aged 55 years and over.

Nova Zelanda - anglès - Medsafe (Medicines Safety Authority)

arrotex pharmaceuticals (nz) limited - phentermine hydrochloride 18.666mg equivalent to phentermine 15mg - modified release capsule - 15 mg - active: phentermine hydrochloride 18.666mg equivalent to phentermine 15mg excipient: brilliant blue fcf gelatin iron oxide black iron oxide yellow lactose monohydrate liquid paraffin magnesium stearate sodium polystyrene sulfonate tekprint black sw-9008 titanium dioxide - management of obesity as a short-term adjunct in a medically monitored comprehensive regimen of weight reduction based on exercise, diet (caloric restriction) and behaviour modification in obese patients with a body mass index (bmi) of 30kg/m² or greater who have not achieved an adequate clinical response to an appropriate weight-reducing regimen alone.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

michaelis bayley holdings pty ltd -

Estats Units - anglès - NLM (National Library of Medicine)

fenwal, inc. - trisodium citrate dihydrate (unii: b22547b95k) (anhydrous citric acid - unii:xf417d3psl), dextrose monohydrate (unii: lx22yl083g) (anhydrous dextrose - unii:5sl0g7r0ok), anhydrous citric acid (unii: xf417d3psl) (anhydrous citric acid - unii:xf417d3psl), sodium phosphate, monobasic, monohydrate (unii: 593yog76rn) (phosphate ion - unii:nk08v8k8hr) -